Extracellular adenosine mediates diverse anti-inflammatory, angiogenic and other signaling effects via binding to adenosine receptors, and also regulates cell proliferation and death via activation of the intrinsic signaling pathways. Given the emerging role of adenosine and other purines in tumor growth and metastasis, this study evaluated the effects of adenosine on the invasion of metastatic prostate and breast cancer cells. Treatment with low micromolar concentrations of adenosine, but not other nucleosides or adenosine receptor agonists, inhibited subsequent cell invasion and migration through matrigel-and laminin-coated inserts. These inhibitory effects occurred via intrinsic receptor-independent mechanisms, despite the abundant expression of A2B adenosine receptors (ADORA2B). Extracellular nucleotides and adenosine were shown to be rapidly metabolized on tumor cell surfaces via sequential ecto-5'-nucleotidase (CD73/NT5E) and adenosine deaminase (ADA) reactions with subsequent cellular uptake of nucleoside metabolites and their intracellular interconversion into ADP/ATP. This was accompanied by concurrent inhibition of AMP-activated Protein Kinase (AMPK) and other signaling pathways. No differences in the proliferation rates, cytoskeleton assembly, expression of major adhesion molecules: integrin-1β (ITGB1), CD44, focal adhesion kinase (FAK), and secretion of matrix metalloproteinases (MMP) were detected between the control and treated cells; thus, excluding the contribution of these components of invasion cascade to the inhibitory effects of adenosine. These data provide a novel insight into the ability of adenosine to dampen immune responses and prevent tumor invasion via two different, adenosine receptor-dependent and independent mechanisms.
Introduction
Despite significant progress in cancer biology, the exact mechanisms underlying tumor growth and metastasis are not fully understood. Reasons for this, among others, include the variety of tumor types, their high plasticity and ability to adapt to environmental challenges, the redundancy of signaling pathways involved, histopathological diversity of the tumor microenvironment, and complex crosstalk between the tumor and supporting stroma as well as other adjacent host cells (1, 2) . Currently, intense research efforts have focused on selective targeting of metabolic and signaling pathways that may be altered during tumorigenesis, with particular emphasis on the extracellular purinergic signalling cascade (3) (4) (5) . The anticancer effects of ATP have been described 25 years ago (6) and since then, evidence is accumulating on potent tumor-suppressing or -promoting roles for ATP, adenosine and other purines (4, 7) .
Most models of purinergic signaling depend on functional interactions between distinct processes. These include (i) release of endogenous ATP and other agonists; (ii) triggering signaling events via a series of ligand-gated P2X and metabotropic P2Y receptors; (iii) ectoenzymatic inactivation of nucleotides; (iii) binding of generated adenosine to its own Gprotein-coupled receptors; and finally, (iv) metabolism and re-uptake of adenosine and other nucleosides by the cells (8) . In view of diverse, often counteracting effects of ATP and adenosine, substantial attention is given to the tumorigenic role of key ectoenzymes mediating stepwise ATP hydrolysis to adenosine: nucleoside triphosphate diphosphohydrolase-1 (NTPDase1, otherwise known as CD39) (9) and ecto-5'-nucleotidase/CD73 (4, (10) (11) (12) . High activities of ecto-5'-nucleotidase/CD73 and other nucleotidases may contribute to the clearance of pro-inflammatory and pro-angiogenic ATP in the tumor environment (4, 7, 9) , simultaneously leading to A 2A adenosine receptor-mediated inhibition of effector immune cells, including cytotoxic T-lymphocytes, natural killer cells, dendritic cells and macrophages (3, 13, 14) . 4 Along with "classical" receptor-mediated pathways, adenosine exerts cytotoxic and other biological effects via intrinsic mechanisms (5, 15, 16) . Most of these effects occur at high micromolar and even millimolar nucleoside concentrations, which are at least two orders of magnitude higher than adenosine receptor affinities and generally imply the uptake of extracellular adenosine and/or its metabolites into the cells through adenosine transporters and their ensuing interconversion into AMP and further to ADP/ATP. As a consequence of these metabolic shifts, adenosine may induce apoptosis of different malignant cells via up-regulation of p53 (17) or AMPK (18) activities, translocation of apoptosis-inducing factor AMID from the cytosol into the nucleus (19) , and other mitochondrial apoptotic pathways (15) . Likewise, high concentrations of adenosine receptor agonists, antagonists and other nucleoside analogues also trigger anti-proliferative and cytotoxic effects on normal and leukemic cells via receptorindependent mechanisms (3, 20, 21) , presumably acting as anti-metabolites competing with natural nucleosides and inhibiting key enzymes of purine homeostasis.
By using androgen-independent prostate carcinoma cells PC-3 and triple-negative breast cancer cells MDA-MB-231 lacking three major biomarkers of breast cancer subtypes (estrogen and progesterone receptors and the epidermal growth factor receptor 2, HER2), as appropriate in vitro models for studying tumor metastasis, this study was undertaken to identify a link between extracellular purines and invasion. The results demonstrate that pre-treatment of tumor cells with low micromolar concentrations of adenosine inhibited their invasion and migration. Strikingly, these effects mainly occurred through the metabolism and uptake of exogenous adenosine with subsequent deregulation of intracellular purine homeostasis and related signalling pathways, thus providing a novel insight into the ability of adenosine to dampen immune responses and inhibit tumor metastasis via two different, adenosine receptor-dependent and independent mechanisms. 
Materials and Methods

Reagents and antibodies
The following antibodies have been used in the study: mouse mAbs against CD44 (Hermes-3), integrin β1 (ITGB1) and isotype-specific 3G6 mAb against chicken T-cells (22) ; rabbit polyclonal anti-phospho-AMPKα1/2 (Thr172) and mouse anti-AMPKα1/2 antibody (Santa Cruz); rabbit polyclonal anti-phospho-AMPK1 (Thr174) and mouse anti-phosphotyrosine mAb (4G10) (Millipore, Temecula, CA); mouse mAbs against focal adhesion kinase (FAK) and phospho-FAK (pY397) (Becton Dickinson Biosciences, CA); mouse monoclonal anti-β-tubulin (TUB2.1) and FITC-conjugated anti-mouse Ig (Sigma-Aldrich); horseradish peroxidase (HRP) conjugated rabbit α-mouse and swine α-rabbit Ig (DAKO A/S, Denmark); Alexa 488 Compound C (also known as dorsomorphin) was from Tocris Biosciences (R&D Systems). 5'-(N-cyclopropyl)-carboxamido-adenosine (CPCA, also known as C103_SIGMA), 5'-N-ethylcarboxamide-adenosine (NECA), lipopolysaccharide (LPS) from Escherichia coli O111:B4, adenosine and other nucleosides and chemicals were purchased from Sigma-Aldrich.
Cell culture and treatments
The PC-3 human prostate carcinoma cell line and the MDA-MB-231 human breast cancer cell line were from ATCC (Manassas, USA 
Invasion and migration assays
The invasion and migration of PC-3 and MDA-MB-231 cells were assayed as described previously (23) . Briefly, the invasion was started by applying a cell suspension (5 x10 3 in 300 μl DMEM-BSA) to the upper chamber of Matrigel-coated cell culture invasion inserts, followed by a 48-hour incubation. Likewise, the migration assay was performed by incubating the cells for 5 hours on the inserts coated with laminin. In both assays, 300 μl of conditioned media from the MG-63 osteosarcoma cell line was placed in the lower chamber as a bone cell-derived chemoattractant to induce invasion and migration. The insert membranes were then fixed with paraformaldehyde, stained with Mayer's haematoxylin and cut off from the inserts. The number of cells on the lower surface was counted with a microscope (10× objective) from 10 consecutive fields representing 40% of the total area of the membrane. (1 mM) were used as positive and negative assay controls, respectively. Cells were harvested using a semi-automated plate harvester (Tomtech MACH III; Fisher Scientific, Hampton, NH) and the incorporated radioactivity was determined by scintillation β-counting.
Measurement of intracellular cAMP
Quantitative PCR
Total RNA was extracted from PC3 and MDA-MB-231 cells using the Nucleo-Spin RNAII Biotecnology. All samples were run as triplicates and the expression values were normalized using human β-actin as an endogenous control.
Flow cytometry
Control and adenosine-treated PC3 cells were either used directly in the assays or additionally seeded for 2 hours onto a matrigel-coated 24-well plate. The cells were resuspended in PBS supplemented with 2% fetal calf serum (FCS) and 0.01% NaN 3 and stained with mouse monoclonal antibodies (100 μl, ~10 μg/ml each) against CD44, integrin β1, as well as isotypespecific mAb 3G6. The cells were then incubated with second-stage FITC-conjugated antimouse Ig and analysed using a FACScan with Cell Quest software (Becton Dickinson, CA).
Immunofluorescence staining
Control and adenosine-treated PC3 cells were plated for 2 hours on a 24-well plate containing 
Western blotting
Control and adenosine-treated PC-3 cells were seeded for 2 hours onto Matrigel-coated 6-well plates. The cells were lysed and subjected to 8% SDS-PAGE electrophoresis (~30 µg protein/lane), followed by transfer of separated proteins to nitrocellulose membranes. The amounts of total and phospho-AMPK1 (Thr174), total and phospho-FAK (pY397), integrin β1, CD44, β-tubulin and phosphotyrosine kinases were determined by using appropriate primary and secondary HRP-conjugated antibodies as described in Supplementary Data.
Thin-layer chromatographic (TLC) analysis of purine-converting pathways
For ecto-5'-nucleotidase and adenosine deaminase (ADA) assays, PC3 and MDA-MB-231 cells were seeded overnight onto 96-well clear plates (8000 cells per well), and incubated at 37°C in a final volume of 100 μl DMEM containing 4 mM β-glycerophosphate and 10 μM of washed and lysed for assaying intracellular content. Nucleotides and nucleosides were separated by reverse-phase HPLC, monitored by absorption at 258 nm and quantified from the areas under the corresponding peaks, as described previously (25) . For more experimental details, see Supplementary Data. Intracellular ATP was additionally determined in the obtained cell lysates by using luciferin-luciferase kit ATPLite (Perkin Elmer).
Human Phospho-Kinase Array
Control and adenosine-treated PC3 and MDA-MB-231 cells were plated for 2 hours onto 6-well plates coated with Matrigel. The phosphorylation profile of major kinases was determined by using the human Phospho-Kinase Array Kit with a cocktail of biotinylated antibodies (R&D Systems, Abingdon, UK) according to the manufacturer's instructions. The protein concentration in cell lysates was determined using the BCA Protein Assay Kit (Pierce, Rockford, IL). After exposing the membranes to a streptavidin-HRP reagent, the obtained images were acquired to the Gel Doc-2000 (Bio-Red Laboratories) and the intensities of the spots were quantified using the accompanying Quantity One software after subtracting the background signal.
Statistical analyses
The experiments were repeated at least three times and each treatment was done as duplicate or triplicate. Data from kinetic experiments were subjected to computer analysis by non-linear least-squares curve fitting (GraphPad Prism, San Diego, CA), and qPCR results were analyzed with the SDS 2.3 software (SABiosciences, Qiagen). Statistical comparisons were made using Student's t test, and P values < 0.05 were taken as significant. (27)) did not affect the numbers of invaded cells (Fig. 1B) . Adenosine, but not other adenosinergic agonists, also diminished the migration of PC-3 cells through laminin, although these inhibitory effects occurred only at relatively high (50 µM) concentrations of the nucleoside (Fig. 1B) .
Inhibitory effects of adenosine are mediated via non-cytotoxic and presumably receptorindependent mechanisms, despite expression of A 2B receptors on PC-3 cells
The most common pathway implicated in adenosine effects includes the activation of certain adenosine receptor(s). In fact, the incubation of PC-3 cells with increasing concentrations of adenosine triggered a concentration-dependent increase in the cAMP level with EC 50 values of ~100 μmol/L ( Fig. 2A) , which could be markedly attenuated in the presence of the A 2B -selective antagonist alloxazine ( 
Adenosine does not affect the expression of adhesion molecules, pattern of cell-matrix interaction and MMP secretion by PC3 cells
To further evaluate the effects of adenosine on the initial binding steps, the expression levels of major adhesion molecules potentially implicated in tumor cell adhesion and metastasis were determined. Flow cytometric and immunoblotting stainings with antibodies against integrin-β1
and CD44 revealed an abundant cell surface expression of these molecules, with no differences in expression levels being detected between the control and adenosine-treated PC-3 cells (Fig. 3) . 
13
Adenosine also did not affect the expression (Fig. 3C ) and staining patterns ( Supplementary Fig.   S1 ) of neither total nor phosphorylated (Y397) forms of yet another important adhesionassociated kinase FAK. Consistent with these staining results, direct kinetic analysis of binding of fluorescently labeled PC-3 cells to matrigel-coated wells showed that adenosine treatment does not affect the maximal binding capacity nor time-course of cell adhesion to extracellular matrix ( Supplementary Fig. S2A ). Furthermore, pretreatment of PC-3 cells with adenosine had no effects on the levels of MMP-2 or MMP-9 accumulated in the inserts during the invasion assay ( Supplementary Fig. S2B ). Taken together, these results exclude the possibility that adenosine-dependent inhibition of PC-3 invasion is mediated via the down-regulation of adhesion molecules, impaired cell-matrix interaction or changes in gelatinase secretion.
Evidence for rapid metabolism of adenosine and other purines by PC-3 cells, followed by uptake of nucleosides and their re-synthesis into intracellular ATP
The following studies were aimed to characterize major pathways involved in adenosine homeostasis. Ecto-5'-nucleotidase/CD73 is known to be a key enzyme responsible for phosphohydrolysis of ATP/ADP-derived extracellular AMP to adenosine (8) . Our qPCR data ( (Fig. 4B) . Concurrent measurement of the whole spectrum of intracellular nucleotides and related compounds demonstrated that, along with ATP as a predominant nucleotide constituent, PC-3 cells contain other nucleotides (ADP, UTP, GTP, ITP and AMP), whereas adenosine and other nucleosides are maintained at very low, nearly undetectable, levels ( Supplementary Fig. S3) . Strikingly, the exposure of PC-3 cells to exogenous adenosine significantly increased the relative amount of intracellular adenosine, accompanied by a concurrent drop in the level of AMP (Fig. 4C) 
Adenosine inhibits phospho-AMPK1α and other signaling pathways in PC-3 cells
At this point, the most evident mechanism(s) underlying the inhibitory effects of adenosine on PC-3 invasion may include its cellular uptake and deregulation of intracellular purine homeostasis and signalling pathways. To address this hypothesis experimentally, we compared the phosphorylation levels of key protein kinases in control and adenosine-treated cells by using an antibody-based array (Fig. 5A, B) . The subsequent quantitative analysis of the array images revealed the ability of adenosine to decrease the phosphorylation levels of certain kinases, including TOR, JNK pan, MEK1/2, AMPK1α and p38a (Fig. 5C) , without affecting the phosphorylation profiles of many other protein kinases (Supplementary Table) . Interestingly, the adenosine-mediated inhibition of phospho-AMPK1α is basically consistent with the above HPLC data on decreased AMP/ATP ratio in adenosine-treated PC-3 cells (see Fig. 4C ). Western blotting analyses further confirmed that, in comparison with untreated controls, adenosinetreated PC-3 cells are characterized by the down-regulation of phospho-AMPK1α (Fig. 6A) .
Additional immunofluorescence stainings with anti-phospho-AMPKα1/2 (Thr172) antibodies also demonstrated that along with predominant nuclear fluorescence, substantial punctate cytosolic green staining was observed in the control and, to lesser extent, adenosine-treated PC-3 cells (Fig. 6B, upper panels) . Staining patterns with antibodies against total AMPKα1/2 were fairly comparable between the control and treated cells (Fig. 6B, middle panels) .
We also examined an overall pattern of phosphotyrosine signalling by using 4G10 mAb to tyrosine kinase substrates. Both control and adenosine-treated PC-3 cells displayed similar phosphorylation profiles, with an abundant tyrosine phosphorylation of several protein bands being detected within a molecular weight range of ~50-140 kDa ( Fig. 6A; lower panel) . These immunoblotting data are consistent with the data on PC3 stainings with 4G10 antibody showing strong green fluorescence in the cortical regions beneath the plasma membranes of both control and treated cells (Fig. 6B, lower panels) . Noteworthy, control and adenosine-treated PC-3 cells 
Treatment of MDA-MB-231 cells with adenosine also diminishes their invasion and affects phosphorylation profiles of AMPK1α and other kinases
Lastly, we evaluated the effects of adenosine on the invasiveness and phospho-kinase profile of another highly invasive cell line, MDA-MB-231 breast cancer cells. These cells also express A 2B receptors (ADORA2B) and CD73 (NT5E) at mRNA levels ( Fig. 7A) , possess high ecto-5'-nucleotidase/CD73 activity (Fig. 7B) , and in addition, are capable of further deaminating adenosine (29) , with subsequent uptake of generated nucleosides and their interconversion into At first sight, the inhibitory effects of adenosine are unexpected, since high ecto-5'-nucleotidase activity is often considered as a poor prognostic factor, which allows the tumors to avoid immune destruction via the generation of immunosuppressive adenosine and deactivation of tumor-infiltrating inflammatory cells (5, 10, 12, 32) . This apparent discrepancy could be resolved based on the following considerations. From the standpoint of adenosine homeostasis and its pharmacological activity, it might be more relevant to examine the ratio of the adenosineproducing capability of ecto-5'-nucleotidase/CD73 to the combined adenosine-utilizing activities (33) . In fact, despite the abundant CD73 expression on tumor cells studied, the generated adenosine was shown to be rapidly deaminated and transported into the cells (see Fig. 4 (14, 32) . On the other hand, the overall pattern of purine homeostasis is markedly deregulated in the tumor environment by hypoxia and metabolic stress, as ascertained by data on constitutively elevated levels of intratumoral ATP (7, 34) , the accelerated rate of nucleotide turnover (4, 9, 33) , and the ability of solid tumors to maintain adenosine gradient, with the highest nucleoside concentrations being reported in the center (14) . Therefore, it may be speculated that besides dampening antitumor immunity, the sustained exposure of tumor cells to the elevated adenosine concurrently impairs their invasiveness (present study) and at higher micromolar concentrations also retards tumor growth and proliferation (15, 21) . This scenario might provide a partial explanation for the well-known phenomena of the high proliferative and invasive capacities of peripheral tumor cells located in the parenchyma and stroma, whereas the core environment of the tumor is maintained in a relatively stable, "semi-quiescent", state (2).
The salient finding of this study is that the effects of adenosine on tumor invasion may extend beyond its receptor-mediated activity. Potential mechanisms of this inhibition involve adenosine metabolism via ecto-adenosine deaminase activity, subsequent cellular uptake and interconversion of transported nucleosides, accompanied by inhibition of several protein kinases, including AMPK1α. AMPK is an energy-sensing serine/threonine kinase consisting of an α-catalytic subunit and regulatory β-and γ-subunits. It is activated under conditions of metabolic stress, such as glucose deprivation, hypoxia and strenuous exercise that deplete intracellular ATP and increase AMP (35) . A number of findings suggest that AMPK-mediated reduction in anabolic pathways may ultimately lead to reduced tumor growth. Hence, pharmacological activation of AMPK would be advantageous in treating different endocrine-related tumors, including prostate and breast cancers (35) (36) (37) 
emerged that lead to the opposite conclusion, stating that inhibition of AMPK reduces cancer growth (35, 36) . In particular, the malignant human prostate tissue was shown to display a higher AMPK activity than normal tissue cells. In addition, the down-regulation of AMPK in prostate cancer cell lines, but not in non-tumorigenic prostate epithelial cells, reduced cell proliferation and induced apoptosis (30, 31) . These conflicting results presumably depend on the tumor type and may also reflect a fine-tuned biphasic regulation of AMPK function and/or changing role of AMPK at different disease states.
Interestingly, short-term (1-10 min) incubation of human endothelial cells (38) as well as rat liver and intestinal epithelial cells (39) with micromolar concentrations of adenosine or its precursor nucleotides triggered a transient activation of AMPK. However, the mechanisms of these acute effects may differ substantially from the chronic effects of adenosine on AMPK inhibition seen in our experimental settings. In addition, the modulation of AMPK in normal and transformed cells often triggers the opposing effects due to differential deletion of downstream tumor suppressors, thus allowing AMPK activation while mitigating the growth-limiting effects of the enzyme (31, 35) . Under conditions of energetic stress and the demand of continuous cell proliferation, AMPK bestows tolerance of cancer cells to nutrient deprivation without restricting cell growth and proliferation (31) . In fact, the decreased AMPK activity in prostate cancer cells challenged to certain energy-starved conditions enhances apoptotic cell death during androgen deprivation and hypoxia (30) and also diminishes their invasive capability when incubated in serum-free media containing adenosine (present study).
Current research on the role of adenosine in tumor pathogenesis and inflammation is particularly focused on targeting the releasing pathways of the precursor nucleotide ATP (7, 34) , directional regulation of ecto-5'-nucleotidase/CD73 activity by using selective enzyme inhibitors, siRNA gene silencing and anti-CD73 mAb therapies (10, 12, 32) (16, 20) . Yet another approach includes tumor treatment with adenosine as a "kindred" metabolite, however most of the pro-apoptotic and anti-proliferative effects of adenosine reported in studies with different malignant cells required continuous presence of supra-physiological nucleoside concentrations (0.1-20 mM) in the assay mixture (15, (17) (18) (19) .
Here, we have shown that adenosine is capable of preventing tumor cell invasion at relatively low concentrations (1-10 μM) without any adverse cytotoxic effects, and that these effects 
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